Effectiveness of pulse dose methyl prednisolone in management of COVID 19: A systematic review and meta-analysis of observational studies.

Authors

  • Rashmi Ranjan Mohanty Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
  • Biswa Mohan Padhy Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
  • Bikash Ranjan Meher Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

DOI:

https://doi.org/10.18433/jpps32430

Abstract

Purpose:

Till date, only systemic corticosteroids have demonstrated definite mortality benefit in management of COVID 19 in various studies. Still certain questions regarding the appropriate dose, duration and timing of corticosteroids remain unanswered. For this reason, the study was planned to determine the efficacy and safety of the pulse dose methyl prednisolone in management of COVID 19 from the publicly available evidence.

Methods:

PubMed, the Cochrane library, ClinicalTrials.gov and medRxiv were searched for articles reporting the use of pulse dose methyl prednisolone in COVID 19 from inception till 31st May, 2021. Odds ratios (ORs) were calculated for estimation of pooled effect by using random effect model and heterogeneity was checked by using I2 statistics.

Results:

Twelve studies (11 observational and 1 RCT) were included in the systematic review. A total of 3110 patients from 9 studies were included in the meta-analysis. Though the use of pulse dose methyl prednisolone demonstrated statistically significant mortality benefit in comparison to usual care (OR=0.71, 95% CI: 0.51 to 0.97, [P=0.03]), (I2= 21%) with calculated Number needed to treat (NNT) of 23.5, there was no statistically significant difference between the use of pulse dose and low dose corticosteroid (OR=0.66, 95% CI: 0.44 to 1.01, [(P=0.05]), (I2= 25%) and the NNT is 23.5. Incidence of adverse events were similar across all the groups. The grade of evidence for primary outcome was of moderate certainty.

Conclusion:

This meta-analysis concurs with the previous reports regarding the use of corticosteroid in COVID 19 in comparison to usual care. However, for both the primary and secondary outcome, the study did not find any statistically significant difference between the use of pulse dose methyl prednisolone and low dose corticosteroid to treat COVID 19 patients

Downloads

Downloads

Published

2022-03-27

How to Cite

Mohanty, R. R. ., Biswa Mohan Padhy, & Meher, B. R. (2022). Effectiveness of pulse dose methyl prednisolone in management of COVID 19: A systematic review and meta-analysis of observational studies. Journal of Pharmacy & Pharmaceutical Sciences, 25, 110–123. https://doi.org/10.18433/jpps32430

Issue

Vol. 25 (2022): Pages 1-

Section

Systematic Review and Meta-Analysis

License

Copyright (c) 2022 Journal of Pharmacy & Pharmaceutical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.